

Press Release

For Immediate release



## Mediso receives Frost & Sullivan New Product Innovation Award

The nanoScan<sup>®</sup> pre-clinical imaging platform was granted with the 2012 European Preclinical Imaging, New Product Innovation Award

**London, United Kingdom – Sept. 27, 2012** – Based on its recent analysis of the European preclinical imaging market, Frost & Sullivan recognizes Mediso Ltd with the 2012 New Product Innovation Award for the nanoScan<sup>®</sup> next generation four modality pre-clinical imaging platform.

nanoScan<sup>®</sup> is the first commercially available fully integrated pre-clinical family of PET/MRI and SPECT/MRI equipment in Europe. It has exclusive design features, such as the proprietary and patented Tera-Tomo™ 3D PET and SPECT engine, MRI Magnet with zero fringe field and InterView™ Fusion, which are tailored to combat the existing issues of attenuation correction, maintenance of homogeneity of the MRI magnetic field and spatial resolution compromise. nanoScan<sup>®</sup> enables easier and more accurate image acquisition with faster reconstruction and post processing to produce fine quality 3D images with 700µm PET and 250µm SPECT spatial resolution, high soft tissue contrast and sensitivity and zero artefact appearance. Frost & Sullivan expects that these innovative features will help nanoScan<sup>®</sup> increase its adoption in the European pre-clinical multimodality systems market to leverage Mediso's leadership position.



“With a strong R&D team, Mediso is at the forefront of technology and product innovation. Its ability to design products without compromising the imaging performance of the different modalities by using a zero fringe field magnet makes its products unmatched. Mediso's ability to provide products that ensure exceptional soft tissue contrast and high sensitivity makes it a strong market player.” notes Frost & Sullivan Research Analyst Somsainathan.C.K. “The company enjoys a strong brand reputation amongst its customers mainly due to its ability to deliver promising technologies for the future of better healthcare. Mediso's product not only maximizes molecular information in combination with precise anatomical detail but also helps the users to spot the exact location, size, nature and extent of malignancy anywhere in the body, which can bring dynamic changes to healthcare delivery in future.”

The nanoScan<sup>®</sup> in vivo molecular imaging platform is developed, manufactured and distributed by Mediso worldwide.

\*Patents for the M<sup>3</sup>-pinhole™ and Tera-Tomo™ technologies are pending.

*Frost & Sullivan presents this award to the company that has demonstrated excellence in developing a product with innovative elements that leverages leading edge technologies, that offers valued added features and benefits, supports increased customer ROI and has the potential for enhanced customer acquisition/penetration.*

*Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.*

**About Mediso Ltd.:**

Mediso is one of the World's largest suppliers of various medical diagnostic and research purpose, single and multimodality imaging devices. The company was founded in 1990 by experts in the largest research and manufacturing company in Europe which has been engaged in nuclear equipment development and production since 1960. Currently Mediso offers 4 imaging modalities - SPECT, PET, CT, MRI - for professionals working in laboratories and nuclear medicine departments. Mediso products are sold worldwide directly and through a network of distributors. There are more than 1000 imaging systems operating in more than 85 countries around the world. For more information about the nanoScan<sup>®</sup> product family and Mediso, please visit the Mediso web site at [www.mediso.com](http://www.mediso.com).

Contact:

Dr. Gábor Németh  
Program Director, Preclinical Imaging  
gabor.nemeth@mediso.hu  
P: +36 (30) 9000-933

**About Frost & Sullivan**

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

- **The Integrated Value Proposition** provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- **The Partnership Infrastructure** is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? To join our Growth Partnership, please visit <http://www.frost.com>.

Contact:

Emily Bailey  
Best Practices  
emily.bailey@frost.com  
P: +44 (0)20 7915 7869